WealthTrust Axiom LLC Increases Position in Haleon plc (NYSE:HLN)

WealthTrust Axiom LLC boosted its holdings in shares of Haleon plc (NYSE:HLN) by 9.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,188 shares of the company’s stock after acquiring an additional 4,796 shares during the period. WealthTrust Axiom LLC’s holdings in Haleon were worth $454,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in Haleon by 0.7% in the 4th quarter. Russell Investments Group Ltd. now owns 966,555 shares of the company’s stock valued at $7,955,000 after purchasing an additional 6,784 shares during the last quarter. Syon Capital LLC boosted its holdings in Haleon by 31.4% in the 4th quarter. Syon Capital LLC now owns 67,711 shares of the company’s stock valued at $557,000 after purchasing an additional 16,175 shares during the last quarter. Marks Group Wealth Management Inc boosted its holdings in Haleon by 5.2% in the 4th quarter. Marks Group Wealth Management Inc now owns 156,894 shares of the company’s stock valued at $1,291,000 after purchasing an additional 7,692 shares during the last quarter. CWM LLC boosted its holdings in Haleon by 13.1% in the 4th quarter. CWM LLC now owns 18,606 shares of the company’s stock valued at $153,000 after purchasing an additional 2,156 shares during the last quarter. Finally, Wealth Alliance lifted its holdings in shares of Haleon by 14.4% in the 4th quarter. Wealth Alliance now owns 38,823 shares of the company’s stock worth $320,000 after acquiring an additional 4,883 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on HLN. HSBC began coverage on shares of Haleon in a report on Wednesday, April 17th. They issued a “buy” rating on the stock. Argus restated a “buy” rating on shares of Haleon in a report on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Haleon currently has an average rating of “Moderate Buy”.

Haleon Price Performance

Haleon stock opened at $8.53 on Wednesday. The firm has a market cap of $38.95 billion, a PE ratio of 30.46, a price-to-earnings-growth ratio of 2.22 and a beta of 0.29. Haleon plc has a 52-week low of $7.70 and a 52-week high of $8.98. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.53. The company’s 50 day moving average is $8.34 and its two-hundred day moving average is $8.29.

Haleon Dividend Announcement

The firm also recently announced a semi-annual dividend, which will be paid on Thursday, May 16th. Shareholders of record on Friday, March 15th will be issued a dividend of $0.1064 per share. The ex-dividend date is Thursday, March 14th. This represents a yield of 1.8%. Haleon’s dividend payout ratio (DPR) is presently 75.00%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.